Acute Kidney Injury Market Size in the 7MM was ~USD 6,230 million in 2022 and It is Expected to Grow by 2034

The Acute Kidney Injury Market in the 7MM was valued at ~USD 6,230 million in 2022, over the forecast period from 2024 to 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Acute Kidney Injury Market Landscape. By analyzing historical data, current Acute Kidney Injury Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Acute Kidney Injury Market is increasingly guided by biomarker-driven strategies. Acute Kidney Injury (AKI) is a sudden and rapid decline in kidney function that occurs over hours to a few days. When the kidneys fail to filter blood properly, waste products, toxins, and excess fluids build up in the body. AKI is often triggered by dehydration, severe infections (sepsis), surgery, certain medications, or reduced blood flow to the kidneys. Symptoms may include decreased urine output, swelling, fatigue, nausea, and confusion, although some patients may show no obvious signs initially. AKI is reversible if diagnosed and treated promptly, but severe or untreated cases can progress to permanent kidney damage or even be life-threatening.

DelveInsight’s report, “Acute Kidney Injury Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Acute Kidney Injury Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions. Additionally, it examines Acute Kidney Injury Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Acute Kidney Injury Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here @ Acute Kidney Injury Market Forecast

Key Takeaways from Acute Kidney Injury Market Report

• The leading Acute Kidney Injury Companies such as Alexion Pharmaceuticals, Alloksys Life Sciences, Am-pharma, Aptabio Therapeutics, Arch Biopartners, Guard Therapeutics, Novartis Pharmaceuticals, Ocelot Bio, Rediscovery Life Sciences, Renibus Therapeutics, River 2 Renal, and others.

• Promising Acute Kidney Injury Therapies such as Conestat alfa (Ruconest®), Neseritide, GDC-8264, THR-184, ABT-719, and others.

• The Acute Kidney Injury Market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching multiple-stage Acute Kidney Injury Pipeline products will significantly revolutionize the Acute Kidney Injury Market Dynamics.

Acute Kidney Injury Overview

Acute Kidney Injury isn’t just a “kidney problem”—it’s a rapid systemic shock affecting nearly every organ. It emerges when the kidneys suddenly lose their ability to fine-tune blood chemistry, electrolyte balance, and urine production, often triggered by events like major surgeries, infections, drug toxicity, or severe dehydration. What makes AKI particularly unique is its “silent onset”: biomarkers like creatinine rise only after damage has already occurred, which means kidney injury is usually underway before clinical tests detect it. Modern research now views AKI as a cascade of endothelial dysfunction, oxidative stress, and inflammatory signaling, not merely a filtration failure. Early intervention—fluid management, medication adjustments, and real-time biomarker monitoring—can dramatically reverse damage, making AKI one of the most time-sensitive and reversible crises in nephrology.

Get a Free sample for the Acute Kidney Injury Market Report @ https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market

Key Trends in the Acute Kidney Injury Therapeutics Market

• Market snapshot & growth trajectory

The 7MM AKI market sits in the multi-billion USD range and is projected to grow throughout the 2024–2034 forecast window driven by rising AKI incidence, ageing populations, and higher hospitalization rates.

• Major unmet need — no approved targeted pharmacologic therapy

Despite decades of research, there remains no broadly approved drug that prevents or directly treats AKI; care is still dominated by supportive measures and renal replacement therapy (dialysis). This persistent unmet need is the single biggest commercial and clinical opportunity.

• Supportive care and RRT continue to dominate near-term revenues

Until disease-modifying drugs arrive, the market economics are driven by dialysis modalities, ICU care costs, off-label use of existing agents, and hospitalization expenses—factors that keep market spend high.

• Strong, diversified pipeline — small molecules, biologics, complement inhibitors, cell/exosome and nanomedicine approaches

The R&D pipeline has broadened: antioxidant and anti-inflammatory small molecules, complement pathway inhibitors, regenerative (stem cell/exosome) therapies, and targeted nanomedicines are all advancing through preclinical and clinical stages. This diversification improves the chance that at least one modality will deliver the first approved AKI therapy.

• Regenerative medicine & exosome/cell approaches are gaining momentum

Preclinical and early clinical work on stem cells and exosome therapies shows promise for tissue repair and functional recovery after AKI — these approaches are now prominent translational priorities.

Acute Kidney Injury Epidemiology Segmentation in the 7MM

The Acute Kidney Injury Market Report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into-

• Total Incident Population of Acute Kidney Injury in Hospitalized Patients
• Mortality Adjusted Incident Population of Acute Kidney Injury in Hospitalized Patients
• Acute Kidney Injury Stage-specific Incident Populatio
• Acute Kidney Injury Age-specific Incident Population 

Download the report to understand which factors are driving Acute Kidney Injury Epidemiology trends @ Acute Kidney Injury Epidemiology Forecast

Recent Development in the Acute Kidney Injury Treatment Landscape

• In December 2025, Genentech Inc. announced a clinical study designed to assess the efficacy and safety of GDC-8264 versus placebo in patients undergoing cardiac surgery who are considered at moderate to high risk of developing Acute Kidney Injury (AKI) and subsequent 90-day Major Adverse Kidney Events (MAKE90). The trial will be executed in two sequential parts (Part 1 and Part 2).
• In December 2025, Novartis Pharmaceuticals conducted a clinical investigation to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) properties of TIN816, while also evaluating its safety and tolerability in hospitalized adult participants in intensive care units presenting with sepsis-associated acute kidney injury (SA-AKI).
• In December 2025, Alexion Pharmaceuticals Inc. initiated a clinical study aiming to evaluate the efficacy of a single intravenous dose of ravulizumab compared with placebo in reducing the risk of clinical consequences of AKI (MAKE) at 90 days in adult participants with chronic kidney disease (CKD) undergoing non-emergent cardiac surgery with cardiopulmonary bypass (CPB).

Acute Kidney Injury Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential Acute Kidney Injury drugs recently launched in the Acute Kidney Injury market or expected to get launched during the study period. The analysis covers Acute Kidney Injury Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Acute Kidney Injury Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acute Kidney Injury Companies and Therapies

•  Genentech Inc.: GDC-8264
• Thrasos Innovation Inc.: THR-184
• AbbVie: ABT-719
• CalciMedica Inc: Auxora
• Quark Pharmaceuticals: QPI-1002

To know more about Acute Kidney Injury Companies working in the treatment market, visit @ Acute Kidney Injury Clinical Trials and Therapeutic Assessment

Acute Kidney Injury Market Drivers

• Rising Incidence of AKI across Healthcare Settings

One of the strongest market drivers is the increasing prevalence of AKI, particularly among hospitalized and critically ill patients. Factors such as sepsis, cardiovascular complications, major surgeries, trauma, and drug-induced nephrotoxicity are contributing to a growing patient pool globally. With aging populations and higher comorbidity rates, the clinical demand for effective AKI management continues to intensify.

• Growing Awareness and Early Diagnosis

Enhanced awareness among clinicians and the adoption of early diagnostic biomarkers—including NGAL, KIM-1, TIMP-2, and IGFBP-7—are enabling faster detection of kidney injury. Early diagnosis significantly improves patient outcomes, which in turn accelerates the uptake of specialized AKI diagnostic tools and therapeutic options.

• Advancements in Critical Care and Renal Replacement Therapies

Critical care advancements and improved access to renal replacement therapies (RRT)—such as continuous renal replacement therapy (CRRT) and hemodialysis—are supporting better management of severe AKI cases. Innovations in CRRT machines, filters, and monitoring technologies are also contributing to the market’s expansion.

• Increasing R&D Efforts and Pipeline Growth

Pharmaceutical companies are intensifying their focus on novel AKI therapeutics, targeting mechanisms such as inflammation, oxidative stress, mitochondrial dysfunction, and vascular injury. The market is being driven by a robust pipeline of investigational agents, representing significant hope for disease-modifying therapies beyond supportive care.

• Rising Burden of Chronic Diseases

The rising prevalence of chronic conditions such as diabetes, hypertension, cardiac disorders, and chronic kidney disease (CKD) increases the risk of AKI significantly. As these conditions become more widespread, the AKI patient population is projected to grow further, reinforcing long-term market potential.

Acute Kidney Injury Market Barriers

• Lack of Early Diagnostic Biomarkers

Timely detection remains difficult as current biomarkers (like serum creatinine) rise only after significant kidney damage. This delays intervention and limits therapeutic success.

• Limited Awareness among Healthcare Providers

Awareness regarding early signs, preventive strategies, and risk factors of AKI is still low in many clinical settings, especially in developing regions.

• Absence of Targeted Pharmacotherapies

Despite ongoing R&D, there are no approved drugs specifically targeting AKI pathophysiology. Most management focuses on supportive care, not disease modification.

• High Clinical Heterogeneity

AKI arises from diverse causes (sepsis, surgery, nephrotoxic agents, dehydration), making it challenging to design standardized and effective treatments.

• High Mortality and Complication Burden

AKI dramatically increases hospitalization duration, morbidity, and mortality. This makes clinical studies complex and costly, impacting commercial interest.

• Complexity in Clinical Trial Design

Variable patient presentation, multifactorial etiology, and lack of unified endpoints hinder late-stage trials and regulatory approvals.

Scope of the Acute Kidney Injury Market Report

1. Coverage- 7MM
2. Study Period- 2020-2034
3. Acute Kidney Injury Companies- Alexion Pharmaceuticals, Alloksys Life Sciences, Am-pharma, Aptabio Therapeutics, Arch Biopartners, Guard Therapeutics, Novartis Pharmaceuticals, Ocelot Bio, Rediscovery Life Sciences, Renibus Therapeutics, River 2 Renal, and others.
4. Acute Kidney Injury Therapies- Conestat alfa (Ruconest®), Neseritide, GDC-8264, THR-184, ABT-719, and others.
5. Acute Kidney Injury Therapeutic Assessment: Acute Kidney Injury current marketed and Acute Kidney Injury emerging therapies
6. Acute Kidney Injury Market Dynamics: Acute Kidney Injury market drivers and Acute Kidney Injury market barriers
7. Acute Kidney Injury Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
8. Acute Kidney Injury Unmet Needs, KOL’s views, Analyst’s views, Acute Kidney Injury Market Access and Reimbursement

Discover more about therapies set to grab major Acute Kidney Injury Market Share @ Acute Kidney Injury Treatment Market

Table of Contents

1. Key Insights

2. Acute Kidney Injury Market Report Introduction

3. Acute Kidney Injury Market Overview at a Glance

4. Acute Kidney Injury Executive Summary

5. Key Events

6. Acute Kidney Injury Market Disease Background and Overview

7. Acute Kidney Injury Methodology

8. Acute Kidney Injury Population

9. Acute Kidney Injury Patient Journey

10. Acute Kidney Injury Marketed Drugs

11. Acute Kidney Injury Emerging Drugs

12. Acute Kidney Injury – 7MM Market Analysis

13. Acute Kidney Injury KOL Views

14. Acute Kidney Injury Unmet Needs

15. Acute Kidney Injury SWOT Analysis

16. Acute Kidney Injury Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.